open access

Vol 53, No 6 (2022)
Original research article
Submitted: 2022-10-14
Accepted: 2022-10-16
Published online: 2022-12-02
Get Citation

Transborder program of allogeneic hematopoietic cell transplantations from unrelated donors for Ukrainian children between 2015–2020 in Bydgoszcz

Jan Styczyński1, Robert Dębski1, Krzysztof Czyżewski1, Monika Richert-Przygońska1
DOI: 10.5603/AHP.a2022.2055
·
Acta Haematol Pol 2022;53(6):407-415.
Affiliations
  1. Department of Pediatric Hematology and Oncology, Jurasz University Hospital 1, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland

open access

Vol 53, No 6 (2022)
ORIGINAL RESEARCH ARTICLE
Submitted: 2022-10-14
Accepted: 2022-10-16
Published online: 2022-12-02

Abstract

Introduction: The aim of this study was the analysis of the organizational aspects, treatments and outcomes of the program of allogeneic hematopoietic stem cell transplantations (HCT) from unrelated donors for children from Ukraine in the Transplant Center in Bydgoszcz, Poland over the period 2015–2020. Material and methods: Patients from Ukraine were referred via email by parents or by the Tabletochki Charity Foundation based in Kyiv directly to transplant physicians or to the Medical Office of Jurasz University Hospital 1 in Bydgoszcz. Results: Overall, 28 allo-matched unrelated donor-HCTs in 22 patients were performed. Children were diagnosed for malignant (n = 19) or non-malignant (n = 3) diseases. Most of the children were in advanced stages of the disease. The cumulative probabilities of hematological engraftment measured by neutrophil and platelet recovery were 90.6% and 77.3%, respectively. The cumulative incidence of acute graft-versus-host disease ≥2° and extensive chronic graft-versus-host disease were 40.9% and 27.7%, respectively. Overall, 11/19 patients with malignant diseases and 1/3 with non-malignant diseases were alive at the end of a median follow-up of 1.5 (range 0.1–6.5) years. Overall survival (OS) for all patients was 0.51 ± 0.11. Patients with malignancies at transplant standard risk had OS = 0.83 ± 0.15, while those with transplant high-risk had OS = 0.34 ± 0.15 (p = 0.025). A total of 10/22 children died. The treatment-related mortality rate was 6/22 (27.3%). The overall relapse rate among children with malignancies was 4/19 (21%). Conclusions: The program of transborder transplants for children from Ukraine was an important factor in international co-operation contributing to the establishment of a program of transplants from unrelated donors for children in Ukraine. The outcome was positive for more than half of the children referred to the program.

Abstract

Introduction: The aim of this study was the analysis of the organizational aspects, treatments and outcomes of the program of allogeneic hematopoietic stem cell transplantations (HCT) from unrelated donors for children from Ukraine in the Transplant Center in Bydgoszcz, Poland over the period 2015–2020. Material and methods: Patients from Ukraine were referred via email by parents or by the Tabletochki Charity Foundation based in Kyiv directly to transplant physicians or to the Medical Office of Jurasz University Hospital 1 in Bydgoszcz. Results: Overall, 28 allo-matched unrelated donor-HCTs in 22 patients were performed. Children were diagnosed for malignant (n = 19) or non-malignant (n = 3) diseases. Most of the children were in advanced stages of the disease. The cumulative probabilities of hematological engraftment measured by neutrophil and platelet recovery were 90.6% and 77.3%, respectively. The cumulative incidence of acute graft-versus-host disease ≥2° and extensive chronic graft-versus-host disease were 40.9% and 27.7%, respectively. Overall, 11/19 patients with malignant diseases and 1/3 with non-malignant diseases were alive at the end of a median follow-up of 1.5 (range 0.1–6.5) years. Overall survival (OS) for all patients was 0.51 ± 0.11. Patients with malignancies at transplant standard risk had OS = 0.83 ± 0.15, while those with transplant high-risk had OS = 0.34 ± 0.15 (p = 0.025). A total of 10/22 children died. The treatment-related mortality rate was 6/22 (27.3%). The overall relapse rate among children with malignancies was 4/19 (21%). Conclusions: The program of transborder transplants for children from Ukraine was an important factor in international co-operation contributing to the establishment of a program of transplants from unrelated donors for children in Ukraine. The outcome was positive for more than half of the children referred to the program.

Get Citation

Keywords

hematopoietic cell transplantation, unrelated donors, transborder program, children

About this article
Title

Transborder program of allogeneic hematopoietic cell transplantations from unrelated donors for Ukrainian children between 2015–2020 in Bydgoszcz

Journal

Acta Haematologica Polonica

Issue

Vol 53, No 6 (2022)

Article type

Original research article

Pages

407-415

Published online

2022-12-02

Page views

1094

Article views/downloads

75

DOI

10.5603/AHP.a2022.2055

Bibliographic record

Acta Haematol Pol 2022;53(6):407-415.

Keywords

hematopoietic cell transplantation
unrelated donors
transborder program
children

Authors

Jan Styczyński
Robert Dębski
Krzysztof Czyżewski
Monika Richert-Przygońska

References (10)
  1. Czyżewski K, Sedláček P, Štěrba J, et al. Progress and trends in pediatric hematopoietic cell transplantation in Central-East European countries. Acta Haematol Pol. 2020; 51(3): 142–150.
  2. Styczynski J, Debski R, Czyzewski K, et al. Acute lymphoblastic leukemia in children: better transplant outcomes after total body irradiation-based conditioning. In Vivo. 2021; 35(6): 3315–3320.
  3. Gałązka P, Styczyński J, Czyżewski K, et al. Impact of decontamination therapy on gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic cell transplantation in children: decontamination therapy in allo-HCT. Curr Res Transl Med. 2021; 69(3): 103298.
  4. Styczynski J, Cheung YK, Garvin J, et al. Outcomes of unrelated cord blood transplantation in pediatric recipients. Bone Marrow Transplant. 2004; 34(2): 129–136.
  5. Styczynski J, Piekarska A, Zaucha-Prażmo A, et al. Antimicrobial prophylaxis in adults and children undergoing hematopoietic cell transplantation: 2021 Polish recommendations. Acta Haematol Pol. 2021; 52(6): 528–542.
  6. Gil L, Kałwak K, Piekarska A, et al. Antifungal management in adults and children with hematological malignancies or undergoing hematopoietic cell transplantation: recommendations of Polish Society of Hematology and Blood Transfusion, Polish Society of Pediatric Oncology and Hematology, and Polish Adult Leukemia Study Group, 2020. Acta Haematol Pol. 2020; 51(2): 60–72.
  7. Styczyński J, Czyżewski K, Ussowicz M, et al. Antimicrobial prophylaxis in patients after hematopoietic cell transplantation: results of a survey of the Polish Federation of Bone Marrow Transplant Centers. Acta Haematol Pol. 2020; 51(3): 183–186.
  8. Sinkó J. Epstein-Barr virus and post-transplant complications: looking for the links. Acta Haematol Pol. 2020; 51(2): 57.
  9. Styczynski J, Tridello G, Gil L, et al. Prognostic impact of Epstein-Barr virus serostatus in patients with nonmalignant hematological disorders undergoing allogeneic hematopoietic cell transplantation: the study of Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation. Acta Haematol Pol. 2020; 51(2): 73–80.
  10. Agulnik A, Kizyma R, Salek M, et al. SAFER Ukraine Collaborative. Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war. Lancet Haematol. 2022; 9(9): e645–e647.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl